Gemphire Therapeutics (NASDAQ:GEMP) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Wednesday, January 17th.
According to Zacks, “Gemphire Therapeutics Inc. is a biopharmaceutical company. It focused on developing and commercializing therapies for the treatment of dyslipidemia. The company’s product candidate is gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies. Gemphire Therapeutics Inc. is headquartered in Northville, Michigan. “
A number of other equities analysts also recently commented on GEMP. Canaccord Genuity restated a “buy” rating on shares of Gemphire Therapeutics in a research note on Friday, October 13th. Roth Capital started coverage on shares of Gemphire Therapeutics in a research note on Thursday, October 19th. They issued a “buy” rating and a $30.00 target price for the company. Piper Jaffray Companies reiterated an “overweight” rating and issued a $22.00 target price on shares of Gemphire Therapeutics in a research note on Friday, October 27th. Finally, HC Wainwright reiterated a “buy” rating and issued a $22.00 target price (up from $21.00) on shares of Gemphire Therapeutics in a research note on Tuesday, November 14th. Two investment analysts have rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $23.17.
Gemphire Therapeutics (NASDAQ GEMP) traded down $0.12 during trading on Wednesday, hitting $6.26. 209,005 shares of the stock were exchanged, compared to its average volume of 128,400. Gemphire Therapeutics has a one year low of $6.07 and a one year high of $21.59. The company has a debt-to-equity ratio of 1.00, a quick ratio of 4.17 and a current ratio of 4.17. The firm has a market cap of $87.89, a P/E ratio of -1.85 and a beta of 3.90.
Gemphire Therapeutics (NASDAQ:GEMP) last posted its quarterly earnings data on Monday, November 13th. The company reported ($0.82) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.68) by ($0.14). analysts expect that Gemphire Therapeutics will post -3.31 earnings per share for the current year.
In other news, insider Steven R. Ph.D. Gullans bought 71,429 shares of the business’s stock in a transaction that occurred on Thursday, February 8th. The stock was acquired at an average cost of $7.00 per share, for a total transaction of $500,003.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 34.00% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the business. Advisory Services Network LLC bought a new position in Gemphire Therapeutics in the 2nd quarter valued at about $139,000. Virtu Financial LLC bought a new position in Gemphire Therapeutics in the 4th quarter valued at about $120,000. Vanguard Group Inc. raised its holdings in Gemphire Therapeutics by 137.6% in the 2nd quarter. Vanguard Group Inc. now owns 30,898 shares of the company’s stock valued at $399,000 after acquiring an additional 17,892 shares during the period. GM Advisory Group Inc. bought a new position in Gemphire Therapeutics in the 2nd quarter valued at about $457,000. Finally, Comerica Bank bought a new position in Gemphire Therapeutics in the 3rd quarter valued at about $850,000. 27.54% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: “Gemphire Therapeutics (GEMP) Downgraded by Zacks Investment Research to Sell” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/12/gemphire-therapeutics-gemp-downgraded-by-zacks-investment-research.html.
About Gemphire Therapeutics
Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.
Get a free copy of the Zacks research report on Gemphire Therapeutics (GEMP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Gemphire Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.